Metformin for Longevity — Evidence, AMPK Activation, and the TAME Trial

Metformin sits at the intersection of diabetes pharmacotherapy and longevity intervention. Observational data in diabetic populations show lower all-cause mortality vs. matched non-diabetic controls. The TAME (Targeting Aging with Metformin) trial will provide the first randomized evidence in non-diabetic adults.

Why metformin sits at this intersection

Metformin was approved for type 2 diabetes in the U.S. in 1994 (used in Europe since 1957). Observational data in diabetic populations show lower all-cause mortality vs. matched non-diabetic controls — a striking signal that motivates longevity-medicine use in non-diabetic adults.

Mechanism

Activates AMPK (cellular energy sensor); inhibits mitochondrial complex I; reduces hepatic gluconeogenesis; modulates gut microbiome. The AMPK activation is mechanistically aligned with caloric restriction.

The TAME trial

TAME (Targeting Aging with Metformin) is the first FDA-approved trial of metformin in non-diabetic adults with aging-related-disease endpoints. The trial design treats aging itself as the intervention target. Results are pending.

Concerns — muscle and exercise

Metformin can blunt the mitochondrial adaptations to exercise (Konopka et al., Aging Cell 2019). Patients prioritizing maximal exercise adaptations may want to discuss timing or alternatives with their physician.

Dosing

Off-label longevity dosing is typically 500–1,500 mg daily, often as extended-release. Most clinicians titrate from 500 mg to manage GI side effects.

NexLife approach

NexLife's longevity program includes metformin under physician oversight by Medical Director Adam Kennah, M.D.. Dosing is individualized.

Sources

• Konopka AR et al., Metformin and exercise — Aging Cell 2019
• TAME trial — afar.org
• Bannister CA et al., Metformin and all-cause mortality — Diabetes Obes Metab 2014